Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Phase I study of FT538, an iPSC-derived NK cell therapy, with daratumumab in R/R multiple myeloma

Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, outlines the rationale of a Phase I study evaluating FT538, an off-the-shelf induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy in combination with daratumumab in relapsed/refractory (R/R) multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.